RDY

13.29

1.06% 0.14

Dopo l'orario di chiusura: 12.86 -0.43 -3.24%

Dr Reddys Laboratories Ltd Adr (RDY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché RDY Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$13.15

Aprire:

$13.3

Volume 24 ore:

1.90M

Relative Volume:

0.80

Capitalizzazione di mercato:

$11.07B

Reddito:

$3.81B

Utile/perdita netta:

$485.75M

Rapporto P/E:

22.63

EPS:

0.5873

Flusso di cassa netto:

$175.50M

1 W Prestazione:

-0.52%

1M Prestazione:

-2.28%

6M Prestazione:

-4.66%

1 anno Prestazione:

-12.51%

Intervallo 1D:

$13.21

$13.36

Intervallo di 1 settimana:

$13.08

$13.43

Portata 52W:

$12.19

$15.71

Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile

Nome

Dr Reddys Laboratories Ltd Adr

Settore

Healthcare (1104)

Industria

Drug Manufacturers - Specialty & Generic (85)

Telefono

Indirizzo

Dipendente

27,527

Cinguettio

@drreddys

Prossima data di guadagno

2026-07-22

Ultimi documenti SEC

RDY's Discussions on Twitter

Compare RDY vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RDY Dr Reddys Laboratories Ltd Adr	13.29	11.07B	3.81B	485.75M	175.50M	0.5873
TAK Takeda Pharmaceutical Co Adr	15.63	49.39B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	8.96	39.55B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.48	36.66B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	78.71	33.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	536.59	22.78B	3.17B	1.29B	1.01B	27.09

Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-23	Downgrade	Goldman	Neutral → Sell
2025-06-05	Aggiornamento	HSBC Securities	Hold → Buy
2024-12-19	Downgrade	Nomura	Buy → Neutral
2024-01-11	Downgrade	Jefferies	Buy → Underperform
2023-08-29	Downgrade	HSBC Securities	Buy → Hold
2023-05-18	Downgrade	Bernstein	Outperform → Mkt Perform
2023-03-17	Aggiornamento	BofA Securities	Neutral → Buy
2023-01-30	Iniziato	JP Morgan	Underweight
2022-11-14	Downgrade	Credit Suisse	Neutral → Underperform
2022-01-03	Ripresa	BofA Securities	Neutral
2021-07-27	Downgrade	Credit Suisse	Outperform → Neutral
2021-02-02	Aggiornamento	Barclays	Equal Weight → Overweight
2020-09-18	Aggiornamento	BofA Securities	Neutral → Buy
2020-09-18	Aggiornamento	Investec	Sell → Hold
2020-01-28	Downgrade	CLSA	Buy → Outperform
2020-01-27	Downgrade	CLSA	Buy → Outperform
2020-01-09	Aggiornamento	Citigroup	Sell → Buy
2019-11-04	Downgrade	BofA/Merrill	Buy → Neutral
2019-09-04	Aggiornamento	Credit Suisse	Underperform → Outperform
2019-07-01	Aggiornamento	Macquarie	Neutral → Outperform
2019-06-20	Iniziato	Deutsche Bank	Hold
2019-06-11	Iniziato	Barclays	Equal Weight
2019-05-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2019-02-19	Aggiornamento	CLSA	Outperform → Buy
2019-01-17	Downgrade	Citigroup	Neutral → Sell
2017-09-21	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2017-08-31	Aggiornamento	CLSA	Underperform → Outperform
2017-07-28	Downgrade	CLSA	Underperform → Sell
2016-07-27	Downgrade	HSBC Securities	Hold → Reduce
2016-07-27	Downgrade	Jefferies	Hold → Underperform
2016-02-10	Aggiornamento	Credit Agricole	Underperform → Buy
2015-11-10	Downgrade	Citigroup	Buy → Neutral

Mostra tutto

Dr Reddys Laboratories Ltd Adr Borsa (RDY) Ultime notizie

07:42 AM

Why Dr. Reddy's Venlafaxine XR capsules quietly matter for everyday patients - AD HOC NEWS

07:42 AM

Jun 18, 2026

Why Dr. Reddy’s Celevida Maxx matters for Indian diabetics - AD HOC NEWS

Jun 18, 2026

Jun 16, 2026

Dr. Reddy's Labs (ADR) Stock (US2565981035): Earnings and valuation keep the ADR in focus - AD HOC NEWS

Jun 16, 2026

Jun 15, 2026

Dr. Reddy's Laboratories Ltd Stock (INE089A01023): U.S. Bosutinib Launch And Pre-market Drop Put ADR - AD HOC NEWS

Jun 15, 2026

Jun 09, 2026

Dr. Reddy's Laboratories stock (INE089A01023): focus on recent FDA progress and US generics growth - AD HOC NEWS

Jun 09, 2026

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.

Jun 09, 2026

Jun 05, 2026

With Lenalidomide Headwinds Behind, Dr. Reddy's Turns to Biosimilars and Consumer Health for Growth - Morningstar

Jun 05, 2026

Dr. Reddy’s (NYSE: RDY) allots 12,100 ESOP shares, updates capital - Stock Titan

Jun 05, 2026

Dr. Reddy’s Laboratories issues 12,100 equity shares under stock options scheme - Business Upturn

Jun 05, 2026

RDY News | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill

Jun 05, 2026

May 31, 2026

Topicus submits revised $2.00 per share proposal for ReadyTech - Investing.com UK

May 31, 2026

Topicus submits revised $2.00 per share proposal for ReadyTech By Investing.com - Investing.com India

May 31, 2026

May 20, 2026